Antiretroviral  ||| S:0 E:15 ||| JJ
prophylaxis  ||| S:15 E:27 ||| NN
for  ||| S:27 E:31 ||| IN
sexual  ||| S:31 E:38 ||| JJ
and  ||| S:38 E:42 ||| CC
injection  ||| S:42 E:52 ||| NN
drug  ||| S:52 E:57 ||| NN
use  ||| S:57 E:61 ||| NN
acquisition  ||| S:61 E:73 ||| NN
of  ||| S:73 E:76 ||| IN
HIV  ||| S:76 E:80 ||| NNP
During  ||| S:80 E:87 ||| IN
the  ||| S:87 E:91 ||| DT
past  ||| S:91 E:96 ||| JJ
few  ||| S:96 E:100 ||| JJ
years ||| S:100 E:105 ||| NNS
,  ||| S:105 E:107 ||| ,
much  ||| S:107 E:112 ||| RB
has  ||| S:112 E:116 ||| VBZ
been  ||| S:116 E:121 ||| VBN
learned  ||| S:121 E:129 ||| VBN
about  ||| S:129 E:135 ||| IN
pre-exposure  ||| S:135 E:148 ||| JJ
prophylaxis  ||| S:148 E:160 ||| NNS
( ||| S:160 E:161 ||| -LRB-
PrEP ||| S:161 E:165 ||| NNP
)  ||| S:165 E:167 ||| -RRB-
of  ||| S:167 E:170 ||| IN
HIV  ||| S:170 E:174 ||| NNP
from  ||| S:174 E:179 ||| IN
studies  ||| S:179 E:187 ||| NNS
conducted  ||| S:187 E:197 ||| VBN
in  ||| S:197 E:200 ||| IN
the  ||| S:200 E:204 ||| DT
U.S.  ||| S:204 E:209 ||| NNP
and  ||| S:209 E:213 ||| CC
elsewhere ||| S:213 E:222 ||| RB
.  ||| S:222 E:224 ||| .
A  ||| S:224 E:226 ||| DT
review  ||| S:226 E:233 ||| NN
and  ||| S:233 E:237 ||| CC
summary  ||| S:237 E:245 ||| NN
was  ||| S:245 E:249 ||| VBD
conducted  ||| S:249 E:259 ||| VBN
of  ||| S:259 E:262 ||| IN
articles  ||| S:262 E:271 ||| NNS
and  ||| S:271 E:275 ||| CC
reports  ||| S:275 E:283 ||| VBZ
published  ||| S:283 E:293 ||| VBN
through  ||| S:293 E:301 ||| IN
August  ||| S:301 E:308 ||| NNP
2012  ||| S:308 E:313 ||| CD
on  ||| S:313 E:316 ||| IN
the  ||| S:316 E:320 ||| DT
safety  ||| S:320 E:327 ||| NN
and  ||| S:327 E:331 ||| CC
efficacy  ||| S:331 E:340 ||| NN
of  ||| S:340 E:343 ||| IN
PrEP  ||| S:343 E:348 ||| JJ
in  ||| S:348 E:351 ||| IN
humans ||| S:351 E:357 ||| NNS
;  ||| S:357 E:359 ||| :
U.S.-based  ||| S:359 E:370 ||| JJ
studies  ||| S:370 E:378 ||| NNS
assessing  ||| S:378 E:388 ||| VBG
PrEP  ||| S:388 E:393 ||| JJ
knowledge ||| S:393 E:402 ||| NN
,  ||| S:402 E:404 ||| ,
attitudes ||| S:404 E:413 ||| NNS
,  ||| S:413 E:415 ||| ,
and  ||| S:415 E:419 ||| CC
use  ||| S:419 E:423 ||| NN
among  ||| S:423 E:429 ||| IN
at-risk  ||| S:429 E:437 ||| JJ
populations  ||| S:437 E:449 ||| NNS
and  ||| S:449 E:453 ||| CC
healthcare  ||| S:453 E:464 ||| JJ
providers ||| S:464 E:473 ||| NNS
;  ||| S:473 E:475 ||| :
and  ||| S:475 E:479 ||| CC
models  ||| S:479 E:486 ||| NNS
of  ||| S:486 E:489 ||| IN
the  ||| S:489 E:493 ||| DT
cost  ||| S:493 E:498 ||| NN
effectiveness  ||| S:498 E:512 ||| NN
of  ||| S:512 E:515 ||| IN
PrEP ||| S:515 E:519 ||| JJ
.  ||| S:519 E:521 ||| .
PrEP  ||| S:521 E:526 ||| NNP
is  ||| S:526 E:529 ||| VBZ
generally  ||| S:529 E:539 ||| RB
safe  ||| S:539 E:544 ||| JJ
and  ||| S:544 E:548 ||| CC
effective  ||| S:548 E:558 ||| JJ
and  ||| S:558 E:562 ||| CC
may  ||| S:562 E:566 ||| MD
be  ||| S:566 E:569 ||| VB
cost  ||| S:569 E:574 ||| VBN
effective  ||| S:574 E:584 ||| JJ
in  ||| S:584 E:587 ||| IN
a  ||| S:587 E:589 ||| DT
targeted  ||| S:589 E:598 ||| JJ
population ||| S:598 E:608 ||| NN
.  ||| S:608 E:610 ||| .
Awareness  ||| S:610 E:620 ||| NNP
and  ||| S:620 E:624 ||| CC
interest  ||| S:624 E:633 ||| NN
in  ||| S:633 E:636 ||| IN
PrEP  ||| S:636 E:641 ||| NNS
are  ||| S:641 E:645 ||| VBP
increasing ||| S:645 E:655 ||| VBG
.  ||| S:655 E:657 ||| .
PrEP  ||| S:657 E:662 ||| NNP
is  ||| S:662 E:665 ||| VBZ
an  ||| S:665 E:668 ||| DT
important  ||| S:668 E:678 ||| JJ
new  ||| S:678 E:682 ||| JJ
addition  ||| S:682 E:691 ||| NN
to  ||| S:691 E:694 ||| TO
HIV  ||| S:694 E:698 ||| NNP
prevention  ||| S:698 E:709 ||| NN
services ||| S:709 E:717 ||| NNS
,  ||| S:717 E:719 ||| ,
but  ||| S:719 E:723 ||| CC
continued  ||| S:723 E:733 ||| JJ
study  ||| S:733 E:739 ||| NN
is  ||| S:739 E:742 ||| VBZ
warranted ||| S:742 E:751 ||| VBN
.  ||| S:751 E:753 ||| .
